this notice of investigation shall be served:

(a) *The complainant is:* Active Wireless Technologies LLC, 104 East Houston Street, Suite 140, Marshall, TX 75670.

(b) The respondents are the following entities alleged to be in violation of section 337, and are the parties upon which the complaint is to be served:

BLU Products, Inc., 8600 NW 36th Street, Suite 300, Doral, FL 33166

Coosea USA Technologies, Inc., 5850 Oberlin Drive, Suite 240, San Diego, CA 92121.

DISH Wireless LLC, 9601 South Meridian Boulevard, Englewood, CO 80112

EchoStar Corporation, 9601 South Meridian Boulevard, Englewood, CO 80112

HTC Corporation, No. 88, Section 3, Zhongxing Road, Xindian, District, New Taipei City 231, Taiwan

LG Electronics Inc., LG Twin Towers, 128 Yeoui-daero, Yeongdeungpo-gu, Seoul, Republic of Korea, 07736

OnePlus Technology (Shenzhen) Co., Ltd., 18C02, 18C03, 18C04, and 18C05, Shum Yip, Terra Building, Binhe Avenue North, Futian, District, Shenzhen, Guangdong, China

Qualcomm Technologies, Inc., 5775 Morehouse Drive, San Diego, CA 92121

TCL Communication Ltd., 5/F, Building 22E, 22 Science Park East Avenue, Hong Kong Science Park, Shatin, New Territories, Hong Kong

TTE Technology, Inc. d/b/a TCL North America, 189 Technology Dr., Irvine, CA 92618

TCL Technology Group Corporation, TCL TECH. Building, 17 Huifeng Third Road, Zhongkai Hi-tech Development District, Huizhou City, Guangdong Province, China

T-Mobile USA, Inc., 12920 SE 38th St., Bellevue, WA 98006

(4) For the investigation so instituted, the Chief Administrative Law Judge, U.S. International Trade Commission, shall designate the presiding Administrative Law Judge.

The Office of Unfair Import Investigations will not participate as a party in this investigation.

Responses to the complaint and the notice of investigation must be submitted by the named respondents in accordance with section 210.13 of the Commission's Rules of Practice and Procedure, 19 CFR 210.13. Pursuant to 19 CFR 201.16(e) and 210.13(a), such responses will be considered by the Commission if received not later than 20 days after the date of service by the Commission of the complaint and the notice of investigation. Extensions of time for submitting responses to the complaint and the notice of investigation will not be granted unless good cause therefor is shown.

Failure of a respondent to file a timely response to each allegation in the complaint and in this notice may be deemed to constitute a waiver of the right to appear and contest the allegations of the complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondent, to find the facts to be as alleged in the complaint and this notice and to enter an initial determination and a final determination containing such findings, and may result in the issuance of an exclusion order or a cease and desist order or both directed against the respondent.

By order of the Commission.

Issued: January 15, 2026.

**Lisa Barton,**

*Secretary to the Commission.*

[FR Doc. 2026–01031 Filed 1–20–26; 8:45 am]

**BILLING CODE 7020–02–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

**[Docket No. DEA–1643]**

### Importer of Controlled Substances Application: Mylan Pharmaceuticals Inc.

**AGENCY:** Drug Enforcement Administration Justice.

**ACTION:** Notice of application.

**SUMMARY:** Mylan Pharmaceuticals Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before February 20, 2026. Such person may also file a hearing on the application on or before February 20, 2026.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *http://www.regulations.gov* and follow the online instructions at the site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *http://www.regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152, and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on December 4, 2025, Mylan Pharmaceuticals Inc., 2829 Manufacturers Road, Greensboro, North Carolina 27406–4600, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

| Controlled substance | Drug code | Schedule |
|---|---|---|
| Remifentanil ..... | 9739 | II |

The company plans to import the listed controlled substance in finished dosage form for commercial distribution to their customers. No other activity for this drug code is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

**Thomas Prevoznik,**

*Deputy Assistant Administrator.*

[FR Doc. 2026–01072 Filed 1–20–26; 8:45 am]

**BILLING CODE 4410–09–P**